Trial Outcomes & Findings for Tobacco Treatment in the Context of Lung Cancer Screening (NCT NCT03927989)

NCT ID: NCT03927989

Last Updated: 2024-11-22

Results Overview

7-day point prevalence abstinence

Recruitment status

COMPLETED

Study phase

NA

Target enrollment

48 participants

Primary outcome timeframe

Week 8 (end of treatment)

Results posted on

2024-11-22

Participant Flow

48 participants were consented in to the study, but 7 withdrew before randomization.

Participant milestones

Participant milestones
Measure
Treatment Arm
Advice to quit and brief discussion of tobacco use plus dual nicotine replacement therapy plus 8 weeks of gain-framed text messages tailored to lung cancer screening patients Text messaging plus nicotine replacement therapy: Brief advice to quit smoking prior to lung cancer screening (LCS), 8 weeks of gain-framed, LCS-tailored text messages, and nicotine replacement therapy.
Standard Care
Advice to quit and brief discussion of tobacco use Standard Care at Lung Cancer Screening: Brief advice to quit smoking prior to lung cancer screening
Overall Study
STARTED
21
20
Overall Study
COMPLETED
21
19
Overall Study
NOT COMPLETED
0
1

Reasons for withdrawal

Reasons for withdrawal
Measure
Treatment Arm
Advice to quit and brief discussion of tobacco use plus dual nicotine replacement therapy plus 8 weeks of gain-framed text messages tailored to lung cancer screening patients Text messaging plus nicotine replacement therapy: Brief advice to quit smoking prior to lung cancer screening (LCS), 8 weeks of gain-framed, LCS-tailored text messages, and nicotine replacement therapy.
Standard Care
Advice to quit and brief discussion of tobacco use Standard Care at Lung Cancer Screening: Brief advice to quit smoking prior to lung cancer screening
Overall Study
Withdrawal by Subject
0
1

Baseline Characteristics

Tobacco Treatment in the Context of Lung Cancer Screening

Baseline characteristics by cohort

Baseline characteristics by cohort
Measure
Treatment Arm
n=21 Participants
Advice to quit and brief discussion of tobacco use plus dual nicotine replacement therapy plus 8 weeks of gain-framed text messages tailored to lung cancer screening patients Text messaging plus nicotine replacement therapy: Brief advice to quit smoking prior to lung cancer screening (LCS), 8 weeks of gain-framed, LCS-tailored text messages, and nicotine replacement therapy.
Standard Care
n=19 Participants
Advice to quit and brief discussion of tobacco use Standard Care at Lung Cancer Screening: Brief advice to quit smoking prior to lung cancer screening
Total
n=40 Participants
Total of all reporting groups
Age, Categorical
<=18 years
0 Participants
n=39 Participants
0 Participants
n=41 Participants
0 Participants
n=35 Participants
Age, Categorical
Between 18 and 65 years
10 Participants
n=39 Participants
11 Participants
n=41 Participants
21 Participants
n=35 Participants
Age, Categorical
>=65 years
11 Participants
n=39 Participants
8 Participants
n=41 Participants
19 Participants
n=35 Participants
Age, Continuous
65.4 years
STANDARD_DEVIATION 6.1 • n=39 Participants
63.4 years
STANDARD_DEVIATION 6.3 • n=41 Participants
64.4 years
STANDARD_DEVIATION 6.2 • n=35 Participants
Sex: Female, Male
Female
12 Participants
n=39 Participants
10 Participants
n=41 Participants
22 Participants
n=35 Participants
Sex: Female, Male
Male
9 Participants
n=39 Participants
9 Participants
n=41 Participants
18 Participants
n=35 Participants
Ethnicity (NIH/OMB)
Hispanic or Latino
0 Participants
n=39 Participants
0 Participants
n=41 Participants
0 Participants
n=35 Participants
Ethnicity (NIH/OMB)
Not Hispanic or Latino
21 Participants
n=39 Participants
19 Participants
n=41 Participants
40 Participants
n=35 Participants
Ethnicity (NIH/OMB)
Unknown or Not Reported
0 Participants
n=39 Participants
0 Participants
n=41 Participants
0 Participants
n=35 Participants
Race (NIH/OMB)
American Indian or Alaska Native
0 Participants
n=39 Participants
0 Participants
n=41 Participants
0 Participants
n=35 Participants
Race (NIH/OMB)
Asian
0 Participants
n=39 Participants
0 Participants
n=41 Participants
0 Participants
n=35 Participants
Race (NIH/OMB)
Native Hawaiian or Other Pacific Islander
0 Participants
n=39 Participants
0 Participants
n=41 Participants
0 Participants
n=35 Participants
Race (NIH/OMB)
Black or African American
5 Participants
n=39 Participants
8 Participants
n=41 Participants
13 Participants
n=35 Participants
Race (NIH/OMB)
White
15 Participants
n=39 Participants
11 Participants
n=41 Participants
26 Participants
n=35 Participants
Race (NIH/OMB)
More than one race
1 Participants
n=39 Participants
0 Participants
n=41 Participants
1 Participants
n=35 Participants
Race (NIH/OMB)
Unknown or Not Reported
0 Participants
n=39 Participants
0 Participants
n=41 Participants
0 Participants
n=35 Participants
Region of Enrollment
United States
21 participants
n=39 Participants
19 participants
n=41 Participants
40 participants
n=35 Participants

PRIMARY outcome

Timeframe: Week 8 (end of treatment)

7-day point prevalence abstinence

Outcome measures

Outcome measures
Measure
Treatment Arm
n=21 Participants
Advice to quit and brief discussion of tobacco use plus dual nicotine replacement therapy plus 8 weeks of gain-framed text messages tailored to lung cancer screening patients Text messaging plus nicotine replacement therapy: Brief advice to quit smoking prior to lung cancer screening (LCS), 8 weeks of gain-framed, LCS-tailored text messages, and nicotine replacement therapy.
Standard Care
n=19 Participants
Advice to quit and brief discussion of tobacco use Standard Care at Lung Cancer Screening: Brief advice to quit smoking prior to lung cancer screening
End of Treatment Abstinence Rates
3 Participants
0 Participants

SECONDARY outcome

Timeframe: 3-month follow-up

Effect size estimates at End of Study

Outcome measures

Outcome measures
Measure
Treatment Arm
n=21 Participants
Advice to quit and brief discussion of tobacco use plus dual nicotine replacement therapy plus 8 weeks of gain-framed text messages tailored to lung cancer screening patients Text messaging plus nicotine replacement therapy: Brief advice to quit smoking prior to lung cancer screening (LCS), 8 weeks of gain-framed, LCS-tailored text messages, and nicotine replacement therapy.
Standard Care
n=19 Participants
Advice to quit and brief discussion of tobacco use Standard Care at Lung Cancer Screening: Brief advice to quit smoking prior to lung cancer screening
End of Study Abstinence Rates
1 Participants
0 Participants

Adverse Events

Treatment Arm

Serious events: 0 serious events
Other events: 0 other events
Deaths: 0 deaths

Standard Care

Serious events: 0 serious events
Other events: 0 other events
Deaths: 0 deaths

Serious adverse events

Adverse event data not reported

Other adverse events

Adverse event data not reported

Additional Information

Dr. Alana Rojewski (PI)

Medical University of South Carolina

Phone: 843-876-1593

Results disclosure agreements

  • Principal investigator is a sponsor employee
  • Publication restrictions are in place